Chemomab Bagged New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Portfolio Pulse from Benzinga Newsdesk
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) has been granted a new European patent for CM-101, its monoclonal antibody in Phase 2 clinical development for treating primary sclerosing cholangitis. The patent strengthens Chemomab's intellectual property for CM-101, which targets CCL24, a key player in fibrosis and inflammation. The global Phase 2 SPRING trial for CM-101 has completed patient enrollment, with results expected by mid-2024.
March 25, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chemomab Therapeutics Ltd. received a new European patent for CM-101, its monoclonal antibody for primary sclerosing cholangitis, with Phase 2 trial results expected by mid-2024.
The granting of a new European patent for CM-101 significantly strengthens Chemomab's intellectual property, potentially increasing its market exclusivity and competitive edge in treating rare fibro-inflammatory diseases. This development is likely to be viewed positively by investors, as it not only validates the company's research and development efforts but also enhances its potential for future revenue generation. The completion of patient enrollment for the Phase 2 SPRING trial and the anticipation of results by mid-2024 further underscore the progress in CM-101's clinical development, potentially driving investor interest and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100